Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC4TQL)

• Drug Name: PMID28092474-Compound-32 Drug Info
• Cross-matching ID: TTD Drug ID: DMC4TQL

Molecule-Related Drug Atlas

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[2]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[3]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[4]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[5]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[6]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[7]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[4]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[9]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
• [2] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [3] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [7] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [8] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [9] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.